Selected research
Industry Research
Cabozantinib (Cometriq) Industry Research Report 2026
Market perspective
The global Cabozantinib (Cometriq) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cabozantinib (Cometriq) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cabozantinib (Cometriq) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cabozantinib (Cometriq) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cabozantinib (Cometriq) include Exelixis, Ipsen and Takeda Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cabozantinib (Cometriq) market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cabozantinib (Cometriq) Market by Company
Exelixis
Ipsen
Takeda Pharmaceutical
Cabozantinib (Cometriq) Segment by Type
Tablet
Capsule
Cabozantinib (Cometriq) Segment by Application
Medullary Thyroid Cancer
Renal Cell Cancer
Hepatocellular Cancer
Cabozantinib (Cometriq) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cabozantinib (Cometriq) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cabozantinib (Cometriq) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cabozantinib (Cometriq).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cabozantinib (Cometriq) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cabozantinib (Cometriq) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cabozantinib (Cometriq) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablet
- Capsule
Applications
- Medullary Thyroid Cancer
- Renal Cell Cancer
- Hepatocellular Cancer
Companies covered
- Exelixis
- Ipsen
- Takeda Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cabozantinib (Cometriq) Market Size (2021-2032)
- 2.2.2 Global Cabozantinib (Cometriq) Sales (2021-2032)
- 2.2.3 Global Cabozantinib (Cometriq) Market Average Price (2021-2032)
- 2.3 Cabozantinib (Cometriq) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablet
- 2.3.3 Capsule
- 2.4 Cabozantinib (Cometriq) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Medullary Thyroid Cancer
- 2.4.3 Renal Cell Cancer
- 2.4.4 Hepatocellular Cancer
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cabozantinib (Cometriq) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cabozantinib (Cometriq) Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Cabozantinib (Cometriq) Revenue of Manufacturers (2021-2026)
- 3.4 Global Cabozantinib (Cometriq) Average Price by Manufacturers (2021-2026)
- 3.5 Global Cabozantinib (Cometriq) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cabozantinib (Cometriq), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cabozantinib (Cometriq), Product Type & Application
- 3.8 Global Manufacturers of Cabozantinib (Cometriq), Established Date
- 3.9 Global Cabozantinib (Cometriq) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Exelixis
- 4.1.1 Exelixis Company Information
- 4.1.2 Exelixis Business Overview
- 4.1.3 Exelixis Cabozantinib (Cometriq) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Exelixis Cabozantinib (Cometriq) Product Portfolio
- 4.1.5 Exelixis Recent Developments
- 4.2 Ipsen
- 4.2.1 Ipsen Company Information
- 4.2.2 Ipsen Business Overview
- 4.2.3 Ipsen Cabozantinib (Cometriq) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Ipsen Cabozantinib (Cometriq) Product Portfolio
- 4.2.5 Ipsen Recent Developments
- 4.3 Takeda Pharmaceutical
- 4.3.1 Takeda Pharmaceutical Company Information
- 4.3.2 Takeda Pharmaceutical Business Overview
- 4.3.3 Takeda Pharmaceutical Cabozantinib (Cometriq) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Takeda Pharmaceutical Cabozantinib (Cometriq) Product Portfolio
- 4.3.5 Takeda Pharmaceutical Recent Developments
5 Global Cabozantinib (Cometriq) Market Scenario by Region
- 5.1 Global Cabozantinib (Cometriq) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cabozantinib (Cometriq) Sales by Region: 2021-2032
- 5.2.1 Global Cabozantinib (Cometriq) Sales by Region: 2021-2026
- 5.2.2 Global Cabozantinib (Cometriq) Sales by Region: 2027-2032
- 5.3 Global Cabozantinib (Cometriq) Revenue by Region: 2021-2032
- 5.3.1 Global Cabozantinib (Cometriq) Revenue by Region: 2021-2026
- 5.3.2 Global Cabozantinib (Cometriq) Revenue by Region: 2027-2032
- 5.4 North America Cabozantinib (Cometriq) Market Facts & Figures by Country
- 5.4.1 North America Cabozantinib (Cometriq) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cabozantinib (Cometriq) Sales by Country (2021-2032)
- 5.4.3 North America Cabozantinib (Cometriq) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cabozantinib (Cometriq) Market Facts & Figures by Country
- 5.5.1 Europe Cabozantinib (Cometriq) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cabozantinib (Cometriq) Sales by Country (2021-2032)
- 5.5.3 Europe Cabozantinib (Cometriq) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cabozantinib (Cometriq) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cabozantinib (Cometriq) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cabozantinib (Cometriq) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cabozantinib (Cometriq) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cabozantinib (Cometriq) Market Facts & Figures by Country
- 5.7.1 South America Cabozantinib (Cometriq) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cabozantinib (Cometriq) Sales by Country (2021-2032)
- 5.7.3 South America Cabozantinib (Cometriq) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cabozantinib (Cometriq) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cabozantinib (Cometriq) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cabozantinib (Cometriq) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cabozantinib (Cometriq) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cabozantinib (Cometriq) Sales by Type (2021-2032)
- 6.1.1 Global Cabozantinib (Cometriq) Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Cabozantinib (Cometriq) Sales Market Share by Type (2021-2032)
- 6.2 Global Cabozantinib (Cometriq) Revenue by Type (2021-2032)
- 6.2.1 Global Cabozantinib (Cometriq) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cabozantinib (Cometriq) Revenue Market Share by Type (2021-2032)
- 6.3 Global Cabozantinib (Cometriq) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cabozantinib (Cometriq) Sales by Application (2021-2032)
- 7.1.1 Global Cabozantinib (Cometriq) Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Cabozantinib (Cometriq) Sales Market Share by Application (2021-2032)
- 7.2 Global Cabozantinib (Cometriq) Revenue by Application (2021-2032)
- 7.2.1 Global Cabozantinib (Cometriq) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cabozantinib (Cometriq) Revenue Market Share by Application (2021-2032)
- 7.3 Global Cabozantinib (Cometriq) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cabozantinib (Cometriq) Value Chain Analysis
- 8.1.1 Cabozantinib (Cometriq) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cabozantinib (Cometriq) Production Mode & Process
- 8.2 Cabozantinib (Cometriq) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cabozantinib (Cometriq) Distributors
- 8.2.3 Cabozantinib (Cometriq) Customers
9 Global Cabozantinib (Cometriq) Analyzing Market Dynamics
- 9.1 Cabozantinib (Cometriq) Industry Trends
- 9.2 Cabozantinib (Cometriq) Industry Drivers
- 9.3 Cabozantinib (Cometriq) Industry Opportunities and Challenges
- 9.4 Cabozantinib (Cometriq) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst